Want to see AU:ACR full AI Analyst Report?
ACR Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume88.57K
Average Volume (3M)120.95K
Market Cap
AU$6.27M
Enterprise ValueAU$8.72M
Total Cash (Recent Filing)AU$946.00K
Total Debt (Recent Filing)AU$3.64M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding522,780,330
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$14.20M
Bulls Say, Bears Say
Bulls Say
Strong Multi-period Revenue Growth TrendSustained and sizeable revenue growth across reporting periods indicates rising end-market uptake of licensed products and milestone realization. Over 2–6 months this trend supports scale effects, improved leverage of fixed costs, and a clearer path to converting higher top-line momentum into sustained licensing income streams.
Very High Reported Gross Margin In 2025A reported 100% gross margin suggests the company’s revenue is largely licensing/IP driven with minimal direct COGS. That structure creates high operating leverage: once sales and royalty streams grow, incremental revenues should flow to the bottom line more directly, supporting margin sustainability if partner royalties persist.
Capital-light, Licensing-based Business ModelA licensing and royalty model reduces need for manufacturing capex and large sales infrastructure, enabling scalable revenue with lower incremental cost. Over months this capital-light structure can preserve cash burn rates, allow focus on IP and partnerships, and make future margin expansion more achievable if partners execute.
Bears Say
High Financial Leverage (debt-to-equity 3.55)A debt-to-equity ratio above 3 indicates elevated solvency risk and interest obligations that constrain strategic flexibility. Over the medium term this leverage can pressure liquidity, limit funding options for new programs or milestone support, and increase vulnerability to partner or market shocks.
Persistent Net Losses And Negative EBIT MarginsOngoing negative net profit and EBIT margins show the business has not yet converted revenue into operating profitability. This reduces retained earnings and undermines ROE, increasing reliance on external funding to support operations and IP development, and weakening the firm’s ability to self-fund commercialization or new licensing initiatives.
Negative Operating And Free Cash FlowsNegative operating and free cash flows indicate the company is burning cash to fund operations or development. Even with modest FCF improvement, persistent negative cash conversion strains liquidity, necessitates financing that can dilute shareholders or increase debt, and raises execution risk for long-term commercial milestones.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$6.27M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 21, 2026 which is in 29 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 522,780,330 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―